Clinical trial NCT01318473: The Use of the ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided With Lesions Smaller Than 15 mm
Official title: A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating the Use of the ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Chest Aspiration and Biopsy With Lesions Smaller Than 15 mm
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cancer
Keywords: cancer
Lead sponsor: ActiViews Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Tel-Aviv Sourasky Medical Center
First posted: 2011-03-18
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This will be a prospective, single-arm, single-center, open-label study to evaluate the use of the ActiSight™ Needle Guidance System in patients with lung lesions smaller than 15 mm undergoing CT-guided percutaneous chest aspiration.

Target location will be in the chest area; the procedure will be performed by a trained physician.

Detailed description: Subjects who are scheduled for clinically indicated percutaneous chest aspiration/biopsy procedures will be screened for inclusion in the study.

Within an 18-day screening period, eligible subjects will be enrolled into the study and undergo percutaneous chest aspiration or percutaneous biopsy utilizing the ActiSight™ Needle Guidance system using CT to guide the needle. Subjects will be followed-up for at least one hour at the clinic for safety and preliminary accuracy evaluations. An erect chest radiograph will be performed within 90 minutes of observation after the chest aspiration to detect the majority of post procedure pneumothoraces. A follow-up visit will be conducted within 7-10 days after the procedure day for safety evaluations.

Eligibility criteria: Inclusion Criteria:

* Male or female subjects, 18 years of age or older at the time of enrollment
* Subjects scheduled for clinically indicated percutaneous chest aspiration/biopsy procedures
* Subjects with lung lesions less than 15 mm.
* Written informed consent to participate in the study
* Ability to comply with the requirements of the study procedures

Exclusion Criteria:

* Subjects who cannot tolerate mild sedation
* Subjects who participated in an active stage of any drug, intervention or treatment trial within 30 days of enrollment.
* Subjects with preexisting conditions which, in the opinion of the investigator, interfere with the conduct of the study.
* Subjects who are uncooperative or cannot follow instructions

Primary outcomes:
measure: Frequency of adequate sample for diagnosis obtained in the procedure as determined from the Histology / Cytology report
timeFrame: 6 month
Secondary outcomes:
measure: Frequency of target reached by the biopsy or aspiration tool, as determined by a qualified physician reviewing the CT images
timeFrame: 6 month
measure: Number of needle punctures through the skin
timeFrame: 6 month
measure: Number of needle punctures through the pleura
timeFrame: 6 month
measure: Number of CT scans needed
timeFrame: 6 month
measure: Duration of procedure: patient preparation, planning, guidance and Cytolog report.
timeFrame: 6 month
Other outcomes:
Locations:
Study officials:
affiliation: Tel-Aviv Sourasky Medical Center
name: Boaz Tiran, Dr.
role: PRINCIPAL_INVESTIGATOR
References: